NIBEC Co., Ltd. (KOSDAQ:138610)
14,870
+80 (0.54%)
At close: Sep 9, 2026
NIBEC Revenue
NIBEC had revenue of 6.06B KRW in the quarter ending June 30, 2026, a decrease of -61.64%. This brings the company's revenue in the last twelve months to 22.60B, down -32.68% year-over-year. In the year 2025, NIBEC had annual revenue of 32.72B with 33.27% growth.
Revenue (ttm)
22.60B
Revenue Growth
-32.68%
P/S Ratio
7.48
Revenue / Employee
235.46M
Employees
96
Market Cap
169.04B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 32.72B | 8.17B | 33.27% |
| Dec 31, 2024 | 24.55B | 8.85B | 56.33% |
| Dec 31, 2023 | 15.70B | -5.97B | -27.53% |
| Dec 31, 2022 | 21.67B | 8.05B | 59.04% |
| Dec 31, 2021 | 13.63B | 7.27B | 114.33% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| ISU Abxis | 51.04B |
| Genome & Company | 24.46B |
| Prestige Biologics | 18.03B |
| Bio Solution | 17.39B |
| TiumBio | 15.00B |
| curacle co.,ltd. | 8.24B |
| Y-Biologics | 3.17B |
| Kangstem Biotech | 3.03B |